Kenneth A. Oye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kenneth A. Oye has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
E Pezalla
Aetna, Inc., Hartford, Connecticut, USA
2 shared publicationsG Hirsch
Center for Biomedical Innovation, MIT, Cambridge, Massachusetts, USA
2 shared publicationsJ Ferguson
Shire, Lexington, Massachusetts, USA
2 shared publicationsA Chia
Singapore Health Sciences Authority Singapore
1 shared publicationA Hoos
Amgen, Zug, Switzerland
1 shared publication- Andrea L. Smidler
Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
1 shared publication
Latest Publications
- 12 September 2016
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 100 (6) , 626-632
Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan
This article describes recent developments in licensing and reimbursement policies in the EU, US, and Japan, examines causes of changes and compares differences and projects trends. With respect to licensing, the European Medicines Agency (EMA), US Food and Drug Administration (FDA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) are committed to rigorous evaluation of pharmaceuticals in advance of market access with feedback from postmarket experience. The EMA is exploring integrated adaptive pathways for licensing, with formal pilot tests to provide a practical proof of concept. The FDA is augmenting traditional licensing procedures through reforms including Breakthrough Product Designation. The PMDA is implementing reforms to foster innovation and earlier patient access through its Sakigake strategy and licensing reforms on regenerative medicines. With respect to reimbursement, several generalizations emerge. Relative to US counterparts, EU payers typically set higher standards for evidence of effectiveness as a condition of reimbursement, impose tougher limits on reimbursement by indication, and drive harder deals in negotiations over prices.
- 12 September 2016
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 100 (6) , 626-632
Pharmaceuticals Licensing and Reimbursement in the European Union, United States, and Japan
This article describes recent developments in licensing and reimbursement policies in the EU, US, and Japan, examines causes of changes and compares differences and projects trends. With respect to licensing, the European Medicines Agency (EMA), US Food and Drug Administration (FDA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) are committed to rigorous evaluation of pharmaceuticals in advance of market access with feedback from postmarket experience. The EMA is exploring integrated adaptive pathways for licensing, with formal pilot tests to provide a practical proof of concept. The FDA is augmenting traditional licensing procedures through reforms including Breakthrough Product Designation. The PMDA is implementing reforms to foster innovation and earlier patient access through its Sakigake strategy and licensing reforms on regenerative medicines. With respect to reimbursement, several generalizations emerge. Relative to US counterparts, EU payers typically set higher standards for evidence of effectiveness as a condition of reimbursement, impose tougher limits on reimbursement by indication, and drive harder deals in negotiations over prices.
- Open Access
- 3 August 2015
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 98 (5) , 514-521
The next frontier: Fostering innovation by improving health data access and utilization
- 3 August 2015
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 98 (5) , 514-521
Open AccessThe next frontier: Fostering innovation by improving health data access and utilization
- 29 August 2014
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 345 (6200) , 1010-1011
Gene drives raise dual-use concerns—Response
- 29 August 2014
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 345 (6200) , 1010-1011
Gene drives raise dual-use concerns—Response
- 8 August 2014
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 345 (6197) , 626-628
Regulating gene drives
Regulatory gaps must be filled before gene drives could be used in the wild
- 8 August 2014
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 345 (6197) , 626-628
Regulating gene drives
Regulatory gaps must be filled before gene drives could be used in the wild
- 1 September 2013
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 94 (3) , 309-311
Legal Foundations of Adaptive Licensing
In April 2012, MIT's Center for Biomedical Innovation and the European Medicines Agency (EMA) cosponsored a workshop on legal foundations of adaptive pharmaceuticals licensing. Past and present attorneys from the US Food and Drug Administration (FDA), the EMA, and Health Sciences Agency Singapore (HSA) found that existing statutes provided authority for adaptive licensing (AL). By contrast, an attorney from Health Canada identified gaps in authority. Reimbursement during initial phases of adaptive approaches to licensing was deemed consistent with existing statutes in all jurisdictions
- 1 September 2013
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 94 (3) , 309-311
Legal Foundations of Adaptive Licensing
In April 2012, MIT's Center for Biomedical Innovation and the European Medicines Agency (EMA) cosponsored a workshop on legal foundations of adaptive pharmaceuticals licensing. Past and present attorneys from the US Food and Drug Administration (FDA), the EMA, and Health Sciences Agency Singapore (HSA) found that existing statutes provided authority for adaptive licensing (AL). By contrast, an attorney from Health Canada identified gaps in authority. Reimbursement during initial phases of adaptive approaches to licensing was deemed consistent with existing statutes in all jurisdictions
- 15 February 2012
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 91 (3) , 426-437
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
Traditional drug licensing approaches are based on binary decisions. At the moment of licensing, an experimental therapy is presumptively transformed into a fully vetted, safe, efficacious therapy. B...
- 15 February 2012
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 91 (3) , 426-437
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
Traditional drug licensing approaches are based on binary decisions. At the moment of licensing, an experimental therapy is presumptively transformed into a fully vetted, safe, efficacious therapy. B...
- Open Access
- 1 September 2009
- Published by Cambridge University Press (CUP) in Politics and the Life Sciences
- Vol. 28 (2) , 2-26
What rough beast? Synthetic biology, uncertainty, and the future of biosecurity
Synthetic biology seeks to create modular biological parts that can be assembled into useful devices, allowing the modification of biological systems with greater reliability, at lower cost, with greater speed, and by a larger pool of people than has been the case with traditional genetic engineering. We assess the offensive and defensive security implications of synthetic biology based on the insights of leading synthetic biologists into how the technology may develop, the projections of practicing biosecurity authorities on changes in the security context and potential security applications of synthetic biology, and joint appraisals of policy relevant sources of uncertainty. Synthetic biology appears to have minimal security implications in the near term, create modest offensive advantages in the medium term, and strengthen defensive capabilities against natural and engineered biological threats and enable novel potential offensive uses in the long term. To maximize defensive and minimize offensive effects of synthetic biology despite uncertainty, this essay suggests a combination of policy approaches, including community-based efforts, regulation and surveillance, further research, and the deliberate design of security and safety features into the technology.
- 1 September 2009
- Published by Cambridge University Press (CUP) in Politics and the Life Sciences
- Vol. 28 (2) , 2-26
Open AccessWhat rough beast? Synthetic biology, uncertainty, and the future of biosecurity
Synthetic biology seeks to create modular biological parts that can be assembled into useful devices, allowing the modification of biological systems with greater reliability, at lower cost, with greater speed, and by a larger pool of people than has been the case with traditional genetic engineering. We assess the offensive and defensive security implications of synthetic biology based on the insights of leading synthetic biologists into how the technology may develop, the projections of practicing biosecurity authorities on changes in the security context and potential security applications of synthetic biology, and joint appraisals of policy relevant sources of uncertainty. Synthetic biology appears to have minimal security implications in the near term, create modest offensive advantages in the medium term, and strengthen defensive capabilities against natural and engineered biological threats and enable novel potential offensive uses in the long term. To maximize defensive and minimize offensive effects of synthetic biology despite uncertainty, this essay suggests a combination of policy approaches, including community-based efforts, regulation and surveillance, further research, and the deliberate design of security and safety features into the technology.
- 1 September 2005
- Published by IWA Publishing in Water Science & Technology
- Vol. 52 (6) , 59-64
The precautionary principle and international conflict over domestic regulation: mitigating uncertainty and improving adaptive capacity
Disputes over invocation of precaution in the presence of uncertainty are building. This essay finds: (1) analysis of past WTO panel decisions and current EU-US regulatory conflicts suggests that appeals to scientific risk assessment will not resolve emerging conflicts; (2) Bayesian updating strategies, with commitments to modify policies as information emerges, may ameliorate conflicts over precaution in environmental and security affairs.
- 1 September 2005
- Published by IWA Publishing in Water Science & Technology
- Vol. 52 (6) , 59-64
The precautionary principle and international conflict over domestic regulation: mitigating uncertainty and improving adaptive capacity
Disputes over invocation of precaution in the presence of uncertainty are building. This essay finds: (1) analysis of past WTO panel decisions and current EU-US regulatory conflicts suggests that appeals to scientific risk assessment will not resolve emerging conflicts; (2) Bayesian updating strategies, with commitments to modify policies as information emerges, may ameliorate conflicts over precaution in environmental and security affairs.